{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:55:43Z","timestamp":1794362143612,"version":"4.9.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020141","name":"Akebia Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Clinical Electrophysiology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jacep.2020.01.004","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T16:48:35Z","timestamp":1587401315000},"page":"351-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":179,"title":["Management of Arrhythmias in Cardiac\u00a0Amyloidosis"],"prefix":"10.1016","volume":"6","author":[{"given":"Shaun","family":"Giancaterino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus A.","family":"Urey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Darden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacep.2020.01.004_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrcardio.2014.165","article-title":"Pathophysiology and treatment of cardiac amyloidosis","volume":"12","author":"Gertz","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib3","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","article-title":"Cardiac amyloidosis: an update on diagnosis and treatment","volume":"84","author":"Donnelly","year":"2017","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jacep.2020.01.004_bib5","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2020.01.004_bib6","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989 [see comments]","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.jacep.2020.01.004_bib7","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacep.2020.01.004_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2020.01.004_bib9","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/01.CIR.0000034511.06350.DF","article-title":"Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation","volume":"106","author":"R\u00f6cken","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2020.01.004_bib10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.jacep.2020.01.004_bib11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0735-1097(97)00267-2","article-title":"Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement","volume":"30","author":"Reisinger","year":"1997","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","article-title":"Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy","volume":"13","author":"Barbhaiya","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacep.2020.01.004_bib13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacep.2020.01.004_bib14","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2009.05.040","article-title":"Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring","volume":"104","author":"Goldsmith","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib15","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1046\/j.1460-9592.2001.01228.x","article-title":"Holter monitoring in AL amyloidosis: prognostic implications","volume":"24","author":"Palladini","year":"2001","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/anec.12032","article-title":"Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis","volume":"18","author":"Boldrini","year":"2013","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0002-9343(77)90870-1","article-title":"The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients","volume":"62","author":"Ridolfi","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.jacep.2020.01.004_bib18","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"Priori","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacep.2020.01.004_bib19","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib20","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2020.01.004_bib21","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2020.01.004_bib22","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ajh.25149","article-title":"Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment","volume":"93","author":"Gertz","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jacep.2020.01.004_bib23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0735-1097(84)80436-2","article-title":"Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities","volume":"3","author":"Falk","year":"1984","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/13506129.2018.1430027","article-title":"Reduced left atrial myocardial deformation irrespective of cavity size: a potential cause for atrial arrhythmia in hereditary transthyretin amyloidosis","volume":"25","author":"Henein","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.jacep.2020.01.004_bib25","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.ehj.2004.04.007","article-title":"Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation","volume":"25","author":"Leone","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacep.2020.01.004_bib26","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacep.2020.01.004_bib27","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","article-title":"Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis","volume":"114","author":"Cyrille","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role","volume":"22","author":"Longhi","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.jacep.2020.01.004_bib29","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacep.2020.01.004_bib30","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1056\/NEJM199211263272205","article-title":"Brief report: atrial systolic failure in primary amyloidosis","volume":"327","author":"Plehn","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2020.01.004_bib31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/hrt.74.5.541","article-title":"Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation","volume":"74","author":"Dubrey","year":"1995","journal-title":"Br Heart J"},{"key":"10.1016\/j.jacep.2020.01.004_bib32","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/hrt.75.4.426-b","article-title":"Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation","volume":"75","author":"Stables","year":"1996","journal-title":"Heart"},{"key":"10.1016\/j.jacep.2020.01.004_bib33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib34","first-page":"1473","article-title":"No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis","volume":"5","author":"Donnellan","year":"2019","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jacep.2020.01.004_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0002-9149(83)90084-X","article-title":"Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients","volume":"52","author":"Roberts","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib36","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"112","author":"Falk","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2020.01.004_bib37","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/thx.37.9.711","article-title":"Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine","volume":"37","author":"Griffiths","year":"1982","journal-title":"Thorax"},{"key":"10.1016\/j.jacep.2020.01.004_bib38","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.jacep.2020.01.004_bib39","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/0002-9149(85)90995-6","article-title":"Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents","volume":"55","author":"Gertz","year":"1985","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib40","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/0003-4819-55-6-989","article-title":"Cardiac amyloidosis. Two cases with digitalis sensitivity","volume":"55","author":"Cassidy","year":"1961","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacep.2020.01.004_bib41","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","author":"Rubinow","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2020.01.004_bib42","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/0002-9149(85)90996-8","article-title":"Selective binding of nifedipine to amyloid fibrils","volume":"55","author":"Gertz","year":"1985","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib43","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","article-title":"Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?","volume":"25","author":"Muchtar","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.jacep.2020.01.004_bib44","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib45","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/jce.13046","article-title":"Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis","volume":"27","author":"Tan","year":"2016","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib46","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/europace\/euz314","article-title":"Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis.","volume":"22","author":"Donnellan","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.jacep.2020.01.004_bib47","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacep.2020.01.004_bib48","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/qjmed\/91.2.141","article-title":"The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement","volume":"91","author":"Dubrey","year":"1998","journal-title":"QJM"},{"key":"10.1016\/j.jacep.2020.01.004_bib49","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/eurheartj\/ehu506","article-title":"A\u00a0study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis","volume":"36","author":"Sayed","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacep.2020.01.004_bib50","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.1002\/clc.20389","article-title":"Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review","volume":"32","author":"Dhoble","year":"2009","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen","year":"2008","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacep.2020.01.004_bib52","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib53","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijcard.2012.08.028","article-title":"Implantable defibrillators in cardiac amyloidosis","volume":"165","author":"van Galen","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib54","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","article-title":"Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis","volume":"222","author":"Hamon","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib55","first-page":"A18064","article-title":"Abstract 18064: outcome of implantable defibrillator therapy in patients with cardiac amyloidosis","volume":"136","author":"Chuzi","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2020.01.004_bib56","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0735-1097(19)31444-5","article-title":"Does an implantable defibrillator alter outcomes in patients with cardiac amyloidosis?","volume":"73","author":"Kim","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib57","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2020.01.004_bib58","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"K\u00f8ber","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2020.01.004_bib59","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2217\/ahe.13.10","article-title":"Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center","volume":"9","author":"Givens","year":"2013","journal-title":"Aging Health"},{"key":"10.1016\/j.jacep.2020.01.004_bib60","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/jce.14180","article-title":"Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality","volume":"30","author":"Donnellan","year":"2019","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib61","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2020.01.004_bib62","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.clml.2016.03.005","article-title":"Bortezomib-containing regimens for the treatment of newly diagnosed and relapsed amyloid light chain amyloidosis: a single-center experience","volume":"16","author":"Jimenez-Zepeda","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jacep.2020.01.004_bib63","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A\u00a0European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jacep.2020.01.004_bib64","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2020.01.004_bib65","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2020.01.004_bib66","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/hrt.78.1.74","article-title":"Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes","volume":"78","author":"Dubrey","year":"1997","journal-title":"Heart"},{"key":"10.1016\/j.jacep.2020.01.004_bib67","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archinte.165.12.1425","article-title":"Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis","volume":"165","author":"Ng","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacep.2020.01.004_bib68","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ahj.2009.08.006","article-title":"Cardiac amyloidosis in African Americans: comparison of\u00a0clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis","volume":"158","author":"Connors","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacep.2020.01.004_bib69","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2020.01.004_bib70","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ahj.2012.04.013","article-title":"The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients","volume":"164","author":"Dungu","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacep.2020.01.004_bib71","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacep.2020.01.004_bib72","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant","volume":"33","author":"Sattianayagam","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacep.2020.01.004_bib73","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/anec.12018","article-title":"The findings of electrocardiography in patients with cardiac amyloidosis","volume":"18","author":"Cheng","year":"2013","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1016\/j.jacep.2020.01.004_bib74","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/13506129.2012.761967","article-title":"Evaluation of patients with cardiac amyloidosis\u00a0using echocardiography, ECG and right heart catheterization","volume":"20","author":"Granstam","year":"2013","journal-title":"Amyloid"},{"key":"10.1016\/j.jacep.2020.01.004_bib75","doi-asserted-by":"crossref","first-page":"A20097","DOI":"10.1161\/circ.132.suppl_3.20097","article-title":"Abstract 20097: Burden of arrhythmias in patients hospitalized with cardiac amyloidosis","volume":"132","author":"Rochlani","year":"2015","journal-title":"Circulation"}],"container-title":["JACC: Clinical Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405500X20300797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405500X20300797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:27:47Z","timestamp":1762500467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405500X20300797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S2405500X20300797"],"URL":"https:\/\/doi.org\/10.1016\/j.jacep.2020.01.004","relation":{},"ISSN":["2405-500X"],"issn-type":[{"value":"2405-500X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Arrhythmias in Cardiac\u00a0Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"JACC: Clinical Electrophysiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacep.2020.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}